Status:
UNKNOWN
Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hyperlipidemias
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How th...
Detailed Description
The lipoprotein response will be performed in 15 healthy individuals recruited by newspaper advertisements. A member of the study team will explain the study in detail on visit 1, and if the individua...
Eligibility Criteria
Inclusion
- Men and women, aged 18 to 60 years.
- Body mass index 20 to 27 kg/m2
Exclusion
- Patients with active inflammatory bowel disease
- Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption
- Patients with active bowel malignancy
- Patients with diabetes mellitus or known/ suspected motility disorders of the gut
- Patients with decompensated liver disease
- Patients on ezetimibe or bile acid sequestrants
- Patients who are pregnant or breastfeeding.
- Patients with renal disease.
- Patients on benzodiazepine.
- Unstable cardiac or respiratory disease
- Any changes to medication in the preceding month
- Patients with hypersensitive to Revestive or any ingredient, active or a history of the drug within the last 5 years
- Patients with GI malignancy (GI tract, hepatobiliary, pancreatic)
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03860688
Start Date
May 1 2019
End Date
May 1 2022
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tornto General Hospital, UHN
Toronto, Ontario, Canada, M5G 1L7